Clinical Trial Update: 9-ING-41 in Pediatric Patients With Refractory Malignancies. [Phase 1]

View source ↗

Summary

Phase 1 trial of 9-ING-41 in pediatric patients with refractory malignancies was terminated; the update does not include study results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma
• Lymphoma
• Meningioma
• Neuroblastoma

Drugs mentioned

• 9-ING-41

Snippet

Sponsor: Actuate Therapeutics Inc. | Conditions: Refractory Cancer, Refractory Neoplasm | Phase 1 | Status: TERMINATED